Big pharma, big data: why drugmakers want your health records
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at BofA/Merrill Lynch on Increased Confidence of Opdivo/Yervoy Approvability
March 5, 2018 9:19 AM ESTBofA/Merrill Lynch raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $68.00 (from $64.00) while maintaining a Buy rating, ahead of the company's CM-227 Opdivo+Yervoy data presentation.
Analyst Jason Gerberry notes a positive outlook on the shares, ahead of BMY's CM-227... More
Pfizer (PFE) Reports Collaboration with Neofludics LLC
March 2, 2018 6:02 AM ESTNeofluidics, LLC announced today that it has entered into a collaboration with Pfizer Inc. (NYSE: PFE) that will attempt to create a first-of-its-kind microfluidics-based platform using Neofluidics' proprietary droplet capture technology to evaluate dynamic drug exposure-response relationships.
Standard in vitro studies performed under static conditions do... More
